Top Page
Fidia Spa
(FDA)
Fidia Spa (FDA) vs. iShares MSCI Italy ETF (EWI)
Fidia Spa Business Overview & Revenue Model
Fidia Spa Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.49M | 28.61M | 24.37M | 23.84M | 21.24M |
| Gross Profit | 12.97M | 19.13M | 1.45M | 15.53M | 13.68M |
| EBITDA | -7.66M | 667.00K | 7.63M | -888.00K | -3.37M |
| Net Income | -9.30M | -1.31M | 5.97M | -3.50M | -5.95M |
Balance Sheet | |||||
| Total Assets | 28.30M | 32.17M | 32.13M | 40.47M | 38.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 3.17M | 4.87M | 5.27M | 4.85M |
| Total Debt | 1.01M | 11.44M | 8.26M | 11.68M | 14.56M |
| Total Liabilities | 25.35M | 28.74M | 4.55M | 42.21M | 37.80M |
| Stockholders Equity | 2.94M | 3.22M | 5.97M | -2.33M | -117.00K |
Cash Flow | |||||
| Free Cash Flow | -4.45M | -5.31M | 495.00K | 498.00K | 3.27M |
| Operating Cash Flow | -4.34M | -4.84M | 793.00K | 584.00K | 3.77M |
| Investing Cash Flow | -47.00K | -357.00K | -231.00K | -57.00K | -181.00K |
| Financing Cash Flow | 2.44M | 3.43M | 747.00K | -1.09M | -1.47M |
Fidia Spa Peers Comparison
Fidia Spa Corporate Events
The Shareholders’ Meeting of Fidia S.p.A. approved the transfer of the company’s registered office from San Mauro Torinese to Turin, along with amendments to several articles of the company’s statute. These changes align with the Board of Directors’ proposals and are part of the company’s ongoing efforts to streamline operations and enhance its strategic positioning in the market.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has released its monthly financial update as of September 30, 2025, in compliance with regulatory requirements. The company has been actively involved in convertible bond loans and capital strengthening operations, which are crucial for its financial and industrial plans. The update includes details on financial positions, overdue debts, and changes in related party relations, reflecting the company’s ongoing efforts to maintain transparency and strategic alignment with its business objectives.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced a change in its share capital following the conversion of bonds into ordinary shares, resulting in an increase of 3,750,000 shares and a capital boost of 750,000 Euros. This move, which raises the total number of shares to 18,977,312, is expected to enhance Fidia’s market presence and operational capacity as it continues to trade on Euronext Milan.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the issuance and conversion of 75 bonds into new shares, increasing its share capital by Euro 750,000 to a total of Euro 8,597,761.90. This strategic move, involving Global Growth Holding Limited, enhances Fidia’s financial structure and market presence, potentially benefiting stakeholders by expanding its capital base and reinforcing its position in the industry.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the termination of employment with its CFO, Dr. Luca Carante, as part of a strategic move to strengthen its organizational structure. The company is actively seeking a new candidate for the CFO and Investor Relations Manager roles, with interim responsibilities being handled by the CEO and Chairman.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has terminated its relationship with Dr. Luca Carante, who held the positions of Group Chief Financial Officer and Investor Relations Manager. This decision is part of a strategic move by the company’s top management to strengthen its organizational structure. In the interim, the CEO and Chairman of the Board will assume these roles until a suitable replacement is found. The company has initiated a selection process to appoint a new CFO and Investor Relations Manager, ensuring compliance with statutory and regulatory requirements.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced a change in its share capital following the conversion of bonds into ordinary shares, resulting in an increase of the share capital by Euro 600,000.00. The total number of shares has risen from 12,452,385 to 15,227,312, all of which are traded on Euronext Milan. This adjustment reflects Fidia’s strategic financial maneuvering to enhance its market position and operational capacity.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 277,777 new shares at a price of Euro 0.18 per share, as part of a convertible bond loan with GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total to Euro 7,847,761.90, and the total number of shares to 15,227,312. This move reflects Fidia’s ongoing financial strategies and its commitment to maintaining a strong market presence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of five bonds into 277,777 new shares at a price of Euro 0.18 per share, as part of a convertible bond loan with GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total number of shares to 14,949,535, and reflects ongoing strategic financial maneuvers to enhance its market position.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced that its Half-Year Financial Report as of June 30, 2025, includes a paragraph from Deloitte & Touche S.p.A. highlighting significant uncertainties regarding business continuity. This disclosure raises concerns about the company’s ongoing operations and could impact its market position and stakeholder confidence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the filing of its Semi-Annual Financial Report as of June 30, 2025, approved by its Board of Directors. This report, which is now accessible to the public through various platforms, reflects the company’s ongoing commitment to transparency and provides stakeholders with critical financial insights that may influence their investment decisions.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has announced the conversion of 10 bonds into 555,554 new shares at a conversion price of Euro 0.18 per share, as requested by GGHL. This conversion is part of a larger convertible bond loan with warrants, which has been partially executed, increasing Fidia’s share capital by Euro 100,000 to a total of Euro 7,747,761.90. The new shares will be admitted to trading on the regulated market, and the company’s total number of shares will rise to 14,671,758. This move reflects Fidia’s ongoing efforts to strengthen its financial position and enhance its market presence.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has reported improved financial results for the first half of 2025, with net revenues increasing by 38.2% compared to the previous year. Despite ongoing geopolitical uncertainties, the company is on track to achieve positive results for the first time in years, supported by a restructuring plan initiated in 2023. The company’s financial performance shows significant improvement, with a reduction in net losses and a positive EBT. Additionally, Fidia has entered into a new investment contract with Global Growth Holding Limited, which has led to an increase in the company’s share capital.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 217,391 new shares at a price of Euro 0.23 per share, as part of a convertible bond loan with warrants reserved for GGHL. This conversion will increase the company’s share capital by Euro 50,000, bringing the total number of shares to 13,878,109. The move reflects Fidia’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting stakeholders by increasing the liquidity and tradability of its shares.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 208,333 new shares at a price of Euro 0.24 per share, as part of a convertible bond loan with warrants reserved for GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total to Euro 7,547,761.90, with 13,660,718 shares now in circulation. This move reflects Fidia’s strategic financial maneuvers to enhance its market position and operational capacity.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of 15 bonds into 600,000 new shares at a price of Euro 0.25 per share, as part of a convertible bond loan with warrants reserved for GGHL. This conversion, which increases the company’s share capital by Euro 150,000 to a total of Euro 7,497,761.90, reflects ongoing capital management efforts and impacts the company’s share structure, with the total number of shares now at 13,452,385.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 200,000 new shares at a price of Euro 0.25 per share, as part of its convertible bond loan with GGHL. This conversion increases the company’s share capital by Euro 50,000, bringing the total number of shares to 12,852,385. The move is part of a larger capital increase strategy, with implications for the company’s market operations and shareholder value.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the conversion of five bonds into 200,000 new shares at a price of Euro 0.25 per share, as part of a convertible bond loan with warrants. This conversion increases the company’s share capital by Euro 50,000, bringing the total to Euro 7,297,761.90 and the total number of shares to 12,652,385. The move is part of a strategic capital increase plan to support the company’s growth and enhance its market position.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. announced the issuance and subscription of the fourth tranche of convertible bonds with warrants by Global Growth Holding Limited, amounting to a total nominal value of 500,000 Euros. This strategic financial move is part of a broader investment agreement, enhancing Fidia’s financial structure and potentially impacting its market positioning by facilitating further capital increases.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
Fidia S.p.A. has been mandated by CONSOB to provide monthly financial updates, including details on its net financial position, overdue debts, and changes in relationships with related parties. The company is currently executing a convertible bond loan agreement with Global Growth Holding Limited, which is part of its strategy to strengthen its financial position. This ongoing financial operation is crucial for maintaining business continuity and supporting its industrial and financial plans.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.